Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination
Trading on The Nasdaq Capital Market under the ticker symbol “PURR”
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 04/19/17 | DEF 14A | Definitive proxy statements |
|
30 | |
| 04/13/17 | UPLOAD | SEC-generated letter |
|
1 | |
| 04/12/17 | CORRESP | A correspondence can be sent as a document with another submission type or can be sent as a separate submission. |
|
3 | |
| 04/12/17 | PRER14A | Preliminary revised proxy soliciting materials |
|
30 | |
| 04/10/17 | UPLOAD | SEC-generated letter |
|
2 | |
| 04/04/17 | 8-K | Current report filing |
|
4 | |
| 04/03/17 | PRE 14A | Preliminary proxy statement not related to a contested matter or merger/acquisition |
|
28 | |
| 04/03/17 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 04/03/17 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 03/31/17 | 10-K | Annual report pursuant to Section 13 and 15(d) |
|
   |
115 |
